The related mechanism of radiotherapy in triple-negative breast cancer

doi:10.3969/j.issn.1007-3969.2014.11.012

Welcome to China Oncology,

China Oncology ›› 2014, Vol. 24 ›› Issue (11): 865-870.doi: 10.3969/j.issn.1007-3969.2014.11.012

Previous Articles Next Articles

The related mechanism of radiotherapy in triple-negative breast cancer

LI Bing-xin¹, FU Shen²

1.Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200032, China; 2. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China

Online:2014-11-30 Published:2015-05-05
Contact: FU Shen E-mail: shen_fu@hotmail.com

Share article

Abstract

Abstract: Radiotherapy is one of the main means of local treatment of breast cancer. Triple negative breast cancer (TNBC) as a molecular subtypes of breast cancer, its biological behavior is special and existing multiple molecular targets, these molecular targets influence the response of ionization radiation through different mechanisms and regulate radiotherapy sensitivity of TNBC This article reviewed the recent advances in radiotherapy and radiosensitivity related molecular targets of TNBC.

Key words: Triple-negative breast cancer, Radiotherapy, Radiosensitivity, Biomarker

LI Bing-xin, FU Shen. The related mechanism of radiotherapy in triple-negative breast cancer[J]. China Oncology, 2014, 24(11): 865-870.

[1]	GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo. The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer [J]. China Oncology, 2024, 34(8): 745-752.
[2]	CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong. The progress of treatment for brain metastases of triple-negative breast cancer [J]. China Oncology, 2024, 34(8): 777-784.
[3]	HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190.
[4]	LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200.
[5]	CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran. A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy [J]. China Oncology, 2024, 34(11): 1036-1044.
[6]	CUI Jianchun, LU Wei, LI Qianyong. Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy [J]. China Oncology, 2024, 34(10): 966-971.
[7]	SUN Chongyuan, ZHAO Dongbing. The progress and future prospects of the application of circulating tumor DNA in the diagnosis and treatment of gastric cancer [J]. China Oncology, 2023, 33(8): 782-789.
[8]	WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen. Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma [J]. China Oncology, 2023, 33(7): 693-700.
[9]	BI Zhao, WANG Yongsheng. New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes [J]. China Oncology, 2023, 33(6): 560-565.
[10]	CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun. Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly [J]. China Oncology, 2023, 33(5): 506-516.
[11]	DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong. Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer [J]. China Oncology, 2023, 33(3): 267-273.
[12]	TANG Tianci, ZHAI Zhoushijia, LI Shengwei, WANG Xiaoshen, NI Xiaochen. Application of generalized equivalent uniform dose optimization in the treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy [J]. China Oncology, 2023, 33(3): 274-281.
[13]	SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109.
[14]	WANG Yu, BI Nan. Advancements in the research of immunomodulatory effects of radiation therapy: from basic to clinical [J]. China Oncology, 2023, 33(12): 1083-1091.
[15]	ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang. Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study [J]. China Oncology, 2023, 33(1): 54-60.

The related mechanism of radiotherapy in triple-negative breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments